CDMO Signal ›
Cell Therapy CDMOs ›
Intas Pharmaceuticals
Watch for changes
Email me this profile
✓ FDA Inspections (3)
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
✓ MHRA GMP (5)
✓ HC GMP (38)
Quick Facts: Intas Pharmaceuticals
Signal Score
62.3/100 (as of 2026-11-12)
Quality Compliance
69.0/100 — OAI classification at Sanand (2022-12-02) — CRITICAL
Headquarters
Ahmedabad, India
Modalities
Cell Therapy
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform
About Intas Pharmaceuticals
Pure-play CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
69.0
OAI classification at Sanand (2022-12-02) — CRITICAL
OAI classification at Selaqui (2025-09-16) — CRITICAL
Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated
Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated
Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated
Sources: FDA Data Dashboard, MHRA GMDP
OAI classification at Sanand (2022-12-02) — CRITICAL · OAI classification at Selaqui (2025-09-16) — CRITICAL · Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated · Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated · Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated · Clean MHRA record: 5 compliant GMP certificates (no deductions)
FDA Inspections 3 on record
Warning Letters 3
Last Inspection Official Action Indicated (OAI) (2025-09-16)
MHRA GMP Certificates 5 on record
Health Canada Non-compliant 2
Most Recent HC Outcome Compliant · 2025-03-15
HC Attribution 38 company-level
OAI classification at Sanand (2022-12-02) — CRITICAL
OAI classification at Selaqui (2025-09-16) — CRITICAL
Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated
Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated
Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated
Clean MHRA record: 5 compliant GMP certificates (no deductions)
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors — no verified data
Modalities Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC Filings Private company
Private company
Financial assessment: 60.0/100
Capacity
53.0
1 manufacturing site: Ahmedabad, IN
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Sites: Ahmedabad, IN
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Ahmedabad, IN
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Intas Pharmaceuticals FDA Inspection History
NAI
VAI
OAI
Date
Site
Type
483 citations posted
Classification
2025-09-16
Intas Pharmaceuticals Ltd.
Selaqui
Company-level
Drug Quality Assurance
Not posted
Official Action Indicated (OAI)
2024-07-12
Intas Pharmaceuticals Limited
Ahmedabad
Company-level
Bioresearch Monitoring
Not posted
No Action Indicated (NAI)
2022-12-02
Intas Pharmaceuticals Limited
Sanand
Company-level
Drug Quality Assurance
Yes
Official Action Indicated (OAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
Intas Pharmaceuticals FDA 483 Findings
11 observations
· 2022-12-02 → 2022-12-02
?
By subsystem
Laboratory Controls
3 (27.3%)
Documentation & Records
3 (27.3%)
CAPA
2 (18.2%)
Other
1 (9.1%)
Environmental Monitoring
1 (9.1%)
Data Integrity
1 (9.1%)
By severity
5 — Critical :
1
4 — Serious :
1
3 — Moderate :
5
2 — Minor :
4
Repeat observations :
0
Most severe findings
Critical (5)
Data Integrity
2022-12-02
21 CFR 211.68(b)
Computer control of master formula records
"Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel."
Serious (4)
Environmental Monitoring
2022-12-02
21 CFR 211.42(c)(10)(iv)
Environmental Monitoring System
"Aseptic processing areas are deficient regarding the system for monitoring environmental conditions."
Moderate (3)
Laboratory Controls
2022-12-02
21 CFR 211.160(a)
Following/documenting laboratory controls
"Established test procedures and laboratory control mechanisms are not followed."
Intas Pharmaceuticals MHRA GMP Compliance 5 certificates
Compliant
Non-Compliant
Certificate
Site
City / Postcode
Inspection Date
Status
UK GMP 17543 Insp GMP 17543/9621-0025 [H]
INTAS PHARMACEUTICALS LIMITED
IN-382210
2025-03-06
COMPLIANT
UK GMP 17543 Insp GMP 17543/9621-0025 [V]
INTAS PHARMACEUTICALS LIMITED
IN-382210
2025-03-06
COMPLIANT
UK GMP 17543 Insp GMP 17543/13361605-0002[H]
INTAS PHARMACEUTICALS LIMITED
IN 248197
2024-02-01
COMPLIANT
UK GMP 17543 Insp GMP 17543/18270974-0007[H]
INTAS PHARMACEUTICALS LIMITED
IN 382213
2020-06-23
COMPLIANT
UK GMP 17543 Insp GMP 17543/1682029-0005[H]
INTAS PHARMACEUTICALS LIMITED
IN-382213
2018-01-29
COMPLIANT
Source: MHRA GMDP Database · Retrieved Nov 21, 2026
Hiring Activity
Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original.
How we collect this
No count for this company yet. The careers board we can read covers more than this business (41 postings on Nov 20, 2026), and we can't yet tell which of those roles belong to it. Why: the board covers the whole group and doesn't say which business unit a role belongs to. We'd rather show no number than one that isn't really this company's.
Frequently Asked Questions About Intas Pharmaceuticals
How many FDA inspections does Intas Pharmaceuticals have on record?
CDMO Signal tracks 3 FDA inspections for Intas Pharmaceuticals, sourced from the FDA inspection database. See the full inspection history above.
Has Intas Pharmaceuticals received an FDA warning letter?
Yes — CDMO Signal has 3 FDA warning letters on record for Intas Pharmaceuticals.
Does Intas Pharmaceuticals hold EMA or MHRA GMP certificates?
CDMO Signal tracks 5 MHRA GMP certificates for Intas Pharmaceuticals.
What is Intas Pharmaceuticals's CDMO Signal Score?
Intas Pharmaceuticals has a Signal Score of 62/100, based on quality, operations, financial stability, and capacity data.
Evaluating Intas Pharmaceuticals for a manufacturing program?
Use the free AI matchmaker to compare Intas Pharmaceuticals against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization?
Contact us to verify or update this profile.
Similar CDMOs
Syngene International
Bengaluru, India
Signal Score: 80.3
Biologics, Cell Therapy
Biocon Biologics
Bengaluru, India
Signal Score: 75.7
Cell Therapy
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy
Compare Intas Pharmaceuticals with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Intas Pharmaceuticals
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.